Pulmonary hypertension encompasses a range of conditions directly or indirectly leading to
elevated pressures within the pulmonary arteries. Five main groups of pulmonary …

There is an unmet need for effective treatment strategies to reduce morbidity and mortality in
patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in …

Pulmonary hypertension (PH) is a heterogeneous and fatal disease of the lung vasculature,
where metabolic and mitochondrial dysfunction may drive pathogenesis. Similar to the …

Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial
hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV …

Pulmonary arterial hypertension is a chronic, progressive disorder of the pulmonary
vasculature with associated pulmonary and cardiac remodeling. PAH was a uniformly fatal …

Pulmonary arterial hypertension (PAH) is a rare disease characterized by pulmonary
vascular remodeling leading to right heart failure and death. To date, despite the three …

The past 2 decades have witnessed a> 40% improvement in mortality for patients with heart
failure and left ventricular systolic dysfunction. This success has coincided with the stepwise …

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated
pulmonary arterial pressure due to increased pulmonary vascular resistance, secondary to …

Pulmonary hypertension (PH) is an often-fatal vascular disease of unclear molecular origins.
The pulmonary vascular remodelling which occurs in PH is characterised by elevated …

In lung vascular cells, mitochondria serve a canonical metabolic role, governing energy
homeostasis. In addition, mitochondria exist in dynamic networks, which serve noncanonical …